EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management

Baljinder Singh, Candace M Day, Sadikalmahdi Abdella, Sanjay Garg

Journal of Controlled Release · 2024-03 · 367 · 402-424

DOI: 10.1016/j.jconrel.2024.01.047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024-03. Verfasst von Baljinder Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 236-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD), is a neurodegenerative disorder that escalates with time, exerting a significant impact on physical and mental health and leading to death. The prevalence of AD is progressively rising along with its associated economic burden and necessitates effective therapeutic approaches in the near future. This review paper aims to offer an insightful overview of disease pathogenesis, current FDA-approved drugs, and drugs in different clinical phases. It also explores innovative formulations and drug delivery strategies, focusing on nanocarriers and long-acting medications (LAMs) to enhance treatment efficacy and patient adherence. The review also emphasizes preclinical evidence related to nanocarriers and their potential to improve drug bioavailability, pharmacokinetics, and pharmacodynamics parameters, while also highlighting their ability to minimize systemic side effects. By providing a comprehensive analysis, this review furnishes valuable insights into different pathophysiological mechanisms for future drug development. It aims to inform the development of treatment strategies and innovative formulation approaches for delivering existing molecules in Alzheimer's disease, ultimately striving to improve patient compliance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansDrug Delivery SystemsDrug DevelopmentTreatment OutcomeBiological Availability

Stichwörter der Autor:innen

AChE inhibitorsAdvanced drug deliveryAlzheimer's diseaseAnti-amyloid antibodiesLong-acting injectablesNMDA receptor blockersNanocarriersNeurodegenerative diseases

Autor:innen und Institutionen

  • Centre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
  • Centre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia. Electronic address: Sanjay.garg@unisa.edu.au.

Zitieren

APA

Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024). Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management. Journal of Controlled Release, 367, 402-424. https://doi.org/10.1016/j.jconrel.2024.01.047

Vancouver

Singh B, Day CM, Abdella S, Garg S. Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management. Journal of Controlled Release. 2024;367:402-424. doi:10.1016/j.jconrel.2024.01.047

BibTeX
@article{Singh2024,
  author = {Singh, Baljinder and Day, Candace M and Abdella, Sadikalmahdi and Garg, Sanjay},
  title = {Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {367},
  pages = {402--424},
  doi = {10.1016/j.jconrel.2024.01.047}
}
Kostenlos starten →